Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
vYF vaccine versus Stamaril in adults
2022-502047-35-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Feb 2023
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
Phase 2 trial of SP0218 and 17D yellow fever vaccine in yellow fever (2 arms), sponsored by Sanofi. Primary endpoint: Seroconversion in EU participants. Planned start Feb 2023; status: authorised.
02
Drugs
SP021817D yellow fever vaccine
03
Conditions
yellow fever
Beyond the preview
Go deeper on 2022-502047-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502047-35-00.